Hepatocellular Carcinoma Clinical Trials

Browse current & upcoming clinical research / studies on Hepatocellular Carcinoma. There are a total of 358 clinical trials for Hepatocellular Carcinoma in 43 countries with 32 trials currently in the United States. 124 are either active and/or recruiting patients or have not yet been completed. Click the title of each study to get the complete details on eligibility, location & other facts about the study.

Other clinical trials

Interventional trials
Determine whether experimental treatments or new ways of using known therapies are safe and effective under controlled environments.
Observational trials
Address health issues in large groups of people or populations in natural settings.
Participants are currently being recruited and enrolled.
Active, not recruiting
Study is ongoing (i.e., patients are being treated or examined), but enrollment has completed.
Not yet recruiting
Participants are not yet being recruited or enrolled.
Enrolling by invitation
Participants are being (or will be) selected from a predetermined population.
The study has concluded normally; participants are no longer being examined or treated (i.e., last patient's last visit has occurred).
Study halted prematurely, prior to enrollment of first participant.
Recruiting or enrolling participants has halted prematurely but potentially will resume.
Recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated.
December 2014 -
TACE is frequently offered to patients with baseline hepatic dysfunction with the purpose of diminishing hepatic tumor burden while patients await transplantation. Without this therapeutic measure, disease may progress beyond UNOS T2 criteria required for organ allocation. The purpose of the study is to determine whether transarterial chemoembolization using doxorubicin-eluting beads (DEB-TACE) can be used safely and effectively to treat patients with liver-only hepatocellular carcinoma (HCC) and baseline hepatic dysfunction.
Sponsor: University of California, San Francisco
Study type: Interventional
December 2014 - December 2016
The primary objective of this phase I dose escalation study is to determine the maximum tolerated dose of TH-302 when administered with doxorubicin via trans-arterial chemo-embolization (TACE) in patients with hepatocellular carcinoma (HCC) who are not transplant candidates and have unresectable disease. HCC is the second leading cause of worldwide cancer death and is generally incurable without liver transplant. TACE can convert about 40% of these patients to transplant candidates. Additionally, in non-transplant HCC patients, TACE confers statistical improvements in overall survival. Selective HCC arterial catheterization during TACE allows for the delivery of concentrated drugs to the liver tumor but the optimal TACE chemotherapy regimen has not yet been determined. TH-302 is a hypoxia inducible agent that can be activated in the hypoxic environment induced by TACE.
Sponsor: Scripps Clinic Cancer Center
Study type: Interventional
November 2014 - February 2016
Assessment of safety and tolerability of ADI-PEG 20 in combination with sorafenib in advanced Hepatocellular Carcinoma (HCC).
Sponsor: Polaris Group
Study type: Interventional
October 2014 -
This is an open label, multi-center, phase II study of BBI503 administered to adult patients with advanced hepatobiliary cancer who have exhausted all currently approved standard anti-cancer treatment options. BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily. Cycles will be repeated until patients are no longer clinically benefiting from therapy. Safety, efficacy and tolerability of BBI503 will be assessed for the duration of study treatment.
Sponsor: Boston Biomedical, Inc
Study type: Interventional
October 2014 - January 2016
The main purpose of this study is to evaluate safety and tolerability of LY2157299 when combined with sorafenib in Japanese hepatocellular carcinoma (HCC) participants.
Sponsor: Eli Lilly and Company
Study type: Interventional
October 2014 -
Phase III, randomized, placebo-controlled trial, aimed to seek the therapeutic benefit of V5 subjects with advanced hepatocellular carcinoma. The results will be compared to placebo. The trial duration is 3 months and will consist of one stage with baseline laboratory evaluation including AFP levels with follow-up at monthly intervals. In addition pre-entry abdominal CT scan and end-study CT scan will be preformed. The clinical evaluation will be quantified according to special performance questionnaire.
Sponsor: Lisichansk Regional Tuberculosis Dispensary
Study type: Interventional
September 2014 - September 2015
This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with advanced HCC and CPB cirrhosis whose disease has progressed while taking 1 prior systemic drug therapy for HCC.
Sponsor: Can-Fite BioPharma
Study type: Interventional
September 2014 - September 2019
The purpose of this research is to compare short-term and long-term efficacy of laparoscopic hepatectomy and radiofrequency ablation in the Treatment of small hepatocellular carcinoma, and provide the evidence for the choice of surgical method from the pathology and cytology.
Sponsor: Southwest Hospital, China
Study type: Interventional
August 2014 - August 2016
To see the safety and efficacy of injecting MG4101 as a secondary treatment after curative liver resection on the patient with advanced HCC who has high risk of recurrence.
Sponsor: Samsung Medical Center
Study type: Interventional
August 2014 - December 2016
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2157299 in participants with hepatocellular carcinoma.
Sponsor: Eli Lilly and Company
Study type: Interventional
Home  •  Browse by Condition  •  Search Clinical Trials
The information found on this site has been provided by in accordance with their terms & conditions. Neither we (, the United States Government, U.S. Department of Health and Human Services, National Institutes of Health, National Library of Medicine, nor any of its agencies, contractors, subcontractors or employees of the United States Government make any warranties, expressed or implied, with respect to data found on this site, and, furthermore, assume no liability, or the results of such use, of any part of the data.